grant

CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T cell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial

Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 30 Sept 2025Deadline 31 Aug 2029
FDANIHUS FederalResearch GrantFY2025
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

PROJECT SUMMARY
The long-term goal of this research is to change the prognosis of relapsed or refractory (r/r) T-cell Non-Hodgkin
Lymphoma (T-NHL) using next-generation chimeric antigen receptor T-cell (CART) immunotherapy. CART
therapy has led to remarkable clinical outcomes in B-cell malignancies, but the needle has not moved for most
other…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →

Explore more

📍 More grants in UNITED STATES🏷 More FDA opportunities🏷 More NIH opportunities🏷 More US Federal opportunities🏢 All nih_reporter opportunities
CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T cell non-Hodgkin lymphoma | Dev Procure